MIROSLAW MAZURCZAK, M.D.
Hematology & Oncology Physician in SIOUX FALLS, South Dakota. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.
What stands out: MIROSLAW MAZURCZAK, M.D. reported a CMS MIPS final score of 76.6912 out of 100, below the 83.1 national average, and filed 954 Medicare Part D claims in 2023. Every figure on this page comes straight from federal CMS records, with no proprietary rating applied.
MIROSLAW MAZURCZAK, M.D. practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 2 hospital affiliations — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
MIROSLAW MAZURCZAK, M.D. at a glance
Below national averagePrimary specialty
Medicare Part D claims
MIPS final score
Specialty distribution in South Dakota
How Hematology & Oncology Physician compares to other specialties among South Dakota providers
Hematology & Oncology Physician share within South Dakota
Hematology & Oncology Physician is one of the more visible NUCC categories in South Dakota
Each bar reflects the share of in-state providers whose primary NUCC taxonomy matches the specialty. Long tail of ~690 NUCC codes folded into "Other" to keep the comparison legible.
Medicare quality performance — MIPS
MIROSLAW MAZURCZAK, M.D.'s 2023 MIPS final score plotted against the Hematology & Oncology Physician national average
- MIPS Final Score
- 76.6912/100
- vs 83.1 national avg · 2023 performance year
MIPS final score (Hematology & Oncology Physician) — 76.6912/100 vs national avg 83.1
Quality benchmarks
- National MIPS avg 2023 reporting year
- Quality dim CMS Quality category
- Cost dim CMS Cost category
- Specialty volume Hematology & Oncology Physician US NPIs
76.6912/100 MIPS final score — 6.4 pts below the 83.1 national average
Quality, Cost, Promoting Interoperability, and Improvement Activities composite score for the 2023 performance year. Specialty: Hematology & Oncology Physician. Quality dim: 78.5693. Cost dim: 44.5681.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
MIROSLAW MAZURCZAK, M.D. is a Hematology & Oncology Physician provider practicing in SIOUX FALLS, South Dakota, according to the CMS National Plan and Provider Enumeration System (NPPES). Credentials: M.D.. NPI: 1437155140. This profile includes practice location, specialty classification, and organizational affiliations from the CMS provider registry. Provider information is self-reported to CMS and updated monthly.
MIROSLAW MAZURCZAK, M.D. appears in the CMS NPPES registry as a Hematology & Oncology Physician provider holding M.D. credentials at 1309 W 17TH ST, SIOUX FALLS, SD, 57104, with a listed phone of (605) 328-8000. NPI 1437155140 was issued on 06/27/2005. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what MAZURCZAK most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 954 prescription claims written by this provider, covering 194 Medicare beneficiaries and totaling roughly $1.6 million in drug spend, split 11% brand-name and 89% generic by claim count, with an opioid prescribing rate of 3.9%. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 76.6912/100 for the 2023 performance year (Quality 78.5693, Cost 44.5681), compared with the national average of 83.1.
Hematology & Oncology Physician is a mid-sized specialty nationwide, with 11,215 enrolled providers across 54 states and an average of 847 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1437155140 |
|---|---|
| Specialty | Hematology & Oncology Physician |
| Credentials | M.D. |
| Gender | Male |
| NPI Issued | 06/27/2005 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm MIROSLAW MAZURCZAK, M.D.'s current license status, disciplinary history, and board certifications with the South Dakota Board of Medical and Osteopathic Examiners in South Dakota before relying on this page for a clinical or care decision.
How we sourced this profile
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
Reporting: Group practice
Hospital and facility affiliations
Facilities where MIROSLAW MAZURCZAK, M.D. bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" — a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.
Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).
Industry payments received (2024) — CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for MIROSLAW MAZURCZAK, M.D.. Source: openpaymentsdata.cms.gov.
Total received
$291
Largest payer
ADC Therapeutics America, Inc.
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
Brand vs generic prescribing mix · Typical
11% brand-name claims vs 89% generic, on 954 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 1,330
- Total Day Supply
- 33,596
- Brand vs Generic
- 11% brand / 89% generic
- Brand Drug Cost
- $1.4M
- Generic Drug Cost
- $181K
- Opioid Claims
- 37 (3.9% rate)
- Antibiotic Claims
- 54
Patient Demographics
- Average Patient Age
- 73.1 years
- Avg HCC Risk Score
- 2.02
- Gender Split
- 59% female / 41% male
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
| Drug | Claims |
|---|---|
| Dexamethasone | 97 |
| Anastrozole | 82 |
| Acyclovir | 68 |
| Prednisone | 53 |
| Tamoxifen Citrate | 52 |
| Prochlorperazine Maleate | 43 |
| Bicalutamide | 35 |
| Olanzapine | 31 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 31 |
| Ondansetron Hcl | 29 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Hematology & Oncology Physician Overview
How MIROSLAW MAZURCZAK, M.D. fits within the Hematology & Oncology Physician landscape nationally.
MIROSLAW MAZURCZAK, M.D.'s 954 claims are above the specialty average of 847.
Nearby Hematology & Oncology Physician Providers in South Dakota
Other clinicians with the same primary specialty enrolled in South Dakota, drawn from the same CMS NPPES roster as MAZURCZAK.
Compare Hematology & Oncology Physician nationally: see state-by-state distribution →
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore South Dakota
Frequently Asked Questions
What is MIROSLAW MAZURCZAK, M.D.'s specialty? ▼
How much does MIROSLAW MAZURCZAK, M.D. prescribe under Medicare Part D? ▼
What is MIROSLAW MAZURCZAK, M.D.'s Medicare quality score? ▼
Where is MIROSLAW MAZURCZAK, M.D. located? ▼
What is MIROSLAW MAZURCZAK, M.D.'s NPI number? ▼
Does MIROSLAW MAZURCZAK, M.D. prescribe more brand-name or generic drugs? ▼
Does MIROSLAW MAZURCZAK, M.D. prescribe opioids? ▼
How many Hematology & Oncology Physician providers are there in the US? ▼
What drugs does MIROSLAW MAZURCZAK, M.D. prescribe most often? ▼
Does MIROSLAW MAZURCZAK, M.D. accept Medicare? ▼
How can I verify MIROSLAW MAZURCZAK, M.D.'s credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology